New drug interaction study aims to make radiprodil safer for future use

NCT ID NCT06975605

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested how the experimental drug radiprodil interacts with five common medications (warfarin, midazolam, digoxin, rosuvastatin, and omeprazole) in 18 healthy adults. Participants took radiprodil alone and then with each of these drugs to measure changes in drug levels and safety. The goal is to understand if radiprodil affects how the body processes other drugs, which is important for planning future trials in people with tuberous sclerosis complex and other neurological disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radiprodil

What this could lead to

If successful, this study will help doctors understand how radiprodil interacts with other drugs, leading to safer dosing in future trials for neurological conditions.

What could go wrong

This is a very early, small study in healthy volunteers, not patients. It only checks drug interactions, not whether radiprodil works for any disease. Results may not predict effects in people with the target conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX (TSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Focal Cortical Dysplasia isolated focal cortical dysplasia tuberous sclerosis tuberous sclerosis 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nucleus Network Melbourne

    Melbourne, Victoria, 3004, Australia